Úvod Laboratorní plasty Zkumavky Microcentrifuge Tube 1.5 ml Microcentrifuge Tube SALSA MLPA P080 Craniofacial probemix - 50 reactions

SALSA MLPA P080 Craniofacial probemix - 50 reactions

SALSA MLPA P080 Craniofacial probemix - 50 reactions

application: Craniofacial disorders
region: FGFRs, TWIST, MSX2, ALX4, RUNX2 Detailní informace

Cena s DPH € 573.54
Cena bez DPH € 474.00
 50 react
Dostupnost Skladem
Kód produktu P080-050R

Nejnovější informace o produktu naleznete exklusivně na stránkách výrobce MRC-Holland www.mlpa.com (nové okno)

Detailní popis SALSA MLPA P080 Craniofacial probemix - 50 reactions

P080-050R SALSA MLPA P080 Craniofacial probemix – 50 rxn

CRANIOFACIAL DISORDERS can be caused by alterations in many different genes. This P080-C1 probemix contains probes for the FGFR1, FGFR2, FGFR3, TWIST1, MSX2, ALX1, ALX3, ALX4, EFNB1 and RUNX2 genes.

The FGFR1 (8p11.23; 18 exons), FGFR2 (10q26.13; 21 exons) and FGFR3 (4p16.3; 19 exons) genes encode fibroblast growth factor receptors and cause a diverse group of skeletal disorders. In general, mutations in FGFR1 and FGFR2 cause most craniosynostosis. The dwarfing syndromes are often associated with FGFR3 mutations.
Deletion of the TWIST1 gene (7p21.1; 2 exons) is the cause of disease in an estimated 11 % of Saethre-Chotzen syndrome patients. Included is also a probe for the TWISTNB (TWIST nearby) gene located at a distance of ~500 kb from TWIST. Large deletions of the TWIST region often result in mental retardation.
Dosage of the MSX2 gene (5q35.2; 2 exons) is critical for human skull development. Enlarged parietal foramina and craniosynostosis can result, respectively, from loss and gain of activity in an MSX2 pathway of calvarial osteogenic differentiation.
Mutations in ALX4 (11p11.2; 4 exons) can result in parietal foramina as well as craniosynostosis (premature fusion of the cranial sutures). Potocki-Shaffer syndrome, also known as the proximal 11p deletion syndrome, is a contiguous gene syndrome caused by deletion of this 11p13-p11 region.
Mutations in the ALX3 gene (1p13.3; 4 exons) can result in frontonasal dysplasia.
The ALX1 gene (CART1; 12q21.31; 4 exons) is known to be essential for normal skull bone development, null mice are born with severe craniofacial defects such as a lacking cranium.
Defects in the RUNX2 gene (6p21.1; 9 exons) cause the dominant disorder cleidocranial dysplasia.
Loss-of-function mutations in the EFNB1 gene (Xq13.1; 5 exons) cause craniofrontonasal syndrome.
In addition, nine reference probes are included, detecting several different autosomal chromosomal locations.

This SALSA® MLPA® probemix is designed to detect deletions/duplications of one or more sequences in the aforementioned genes in a DNA sample. Heterozygous deletions of recognition sequences on autosomal chromosomes should give a 35-50% reduced relative peak height of the amplification product of that probe. Deletions of a  probe’s recognition sequence on the X-chromosome will lead to a complete absence of the corresponding probe amplification product in males, whereas female heterozygotes are recognisable by a 35-50% reduction in relative peak height. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak height, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings. We have no information on what percentage of defects in these genes is caused by deletions/duplications of complete exons. Finally, note that most defects in this gene are expected to be small (point) mutations which will not be detected by this SALSA® MLPA® test.

Kontaktujte nás

BIOGEN PRAHA s.r.o.
Ke sv. Izidoru 2293/4A
140 00 PRAHA 4

Tel.: +420 241 401 693
Fax: +420 241 401 694
E-mail: biogen@biogen.cz

Novinky na e-mail

Vaše osobní údaje nejsou nikde zveřejňovány a splňují požadavky GDPR.